Remove tag cost-effectiveness
article thumbnail

STAT+: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices

STAT

By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products. But neither factor has much effect, the studies concluded.

98
article thumbnail

STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more

STAT

Senate Committee on Health, Education, Labor and Pensions is investigating the prices Novo Nordisk charges for its blockbuster medications, Ozempic and Wegovy, which are highly effective at treating diabetes and obesity but carry steep price tags, The New York Times writes. Bernie Sanders (I-Vt.), per package.

Packaging 102
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap

STAT

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two

77
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

While MS is not a terminal diagnosis, the effect of the disease on the CNS can significantly impact patients’ independence and disturb their daily lives. DMTs for MS have a high price tag, particularly in the US. However, they cannot provide a cure and have a very limited impact on halting disease progression.

98
article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies. million price tag. With greater durability, the treatment could turn out to be highly cost effective, he adds.

FDA 111
article thumbnail

STAT+: Pharmalittle: Vertex exec says prices for gene therapies are ‘in the ballpark’; insulin access in poor countries remains spotty

STAT

million tag as cost effective for a Bluebird Bio drug called Zynteglo for the blood disorder beta thalassemia, Arbuckle said in an interview.  Even a drug-price watchdog, the Institute for Clinical and Economic Review, deemed the $2.8

87
article thumbnail

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

pharmaphorum

The cost-effectiveness agency had turned down Evrysdi (risdiplam) in draft guidance published in June, saying it was too expensive, but after negotiations with Roche has reached a deal that will make the drug available to around 1,500 people in England.

98